TY - JOUR
T1 - New therapeutics for chronic heart failure
AU - Mann, Douglas L.
AU - Deswal, Anita
AU - Bozkurt, Biykem
AU - Torre-Amione, Guillermo
PY - 2002
Y1 - 2002
N2 - Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.
AB - Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.
KW - Adrenergic nervous system
KW - Cyokines
KW - Left ventricular remodeling
KW - Renin angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=0036183553&partnerID=8YFLogxK
U2 - 10.1146/annurev.med.53.082901.104004
DO - 10.1146/annurev.med.53.082901.104004
M3 - Review article
C2 - 11818463
AN - SCOPUS:0036183553
SN - 0066-4219
VL - 53
SP - 59
EP - 74
JO - Annual review of medicine
JF - Annual review of medicine
ER -